菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Early-Stage Developability Assessment Services

Micro Developability: High Throughput & Low Sample Consumption

Micro Developability: High-Throughput Developability Assessment Services for Lead Optimization in Drug Discovery


Micro Developability platform provides a high-throughput (HTP) analytical suite that requires <1 mg of antibody per assay. This platform utilizes in silico screening and HTP in vitro assays for sequence liability, biophysical properties, pharmacokinetics (PK), stability, and manufacturability assessments. By analyzing critical aspects with advanced analytics tools like LC-MS, these early developability assessments help optimize leads in drug discovery, mitigate downstream risks, and facilitate a seamless transition to CMC development.

Want to reduce late-stage risks early? Submit the form to get started.

 

 

 

 

In Silico Analysis

 

Our in silico analysis provides liability & CDR hotspot, aggregation, and immunogenicity risk assessment based on the amino acid sequence and structure prediction.

 

Case Study

 

 

Pharmacokinetics (PK)-Predicting Assays

 

To address factors contributing to poor PK profiles, we offer a panel of high-throughput, sensitive, and robust in vitro assays to assess PK properties and predict PK behaviors.

 

Case Study

 

 

Forced Degradation Studies

 

Forced degradation studies under different stress conditions, such as low pH, high temperatures, and freeze-thaw cycles, are critical to identify potential stability risks.

 

Case Study

 

 

Need a customizable package for lead optimization in drug discovery? Speak to the Experts!

Contact Us

In Silico Analysis Identifying Sequence Liability, Aggregation, and Immunogenicity Risks

This case study highlights the use of in silico screening to identify key sequence liabilities and risks. Through targeted evaluation of CDR regions, we detected potential deamidation or isomerization sites. PTM analysis revealed tyrosine sulfation risks, while aggregation scoring identified a hydrophobic patch with aggregation potential.

 

 

BVP/DNA/Insulin ELISA for Non-Specific Binding Evaluation

 

In this case study, mAb3 showed little poly-reactivity, suggesting a good pharmacokinetics (PK) profile. Alternatively, mAb1 and mAb2 exhibited significant concentration-dependent binding to BVP, DNA and insulin, suggesting high risks and poor PK profiles.

 

 

Charge Variant Shifts Under Thermal Stress for Stability Study

 

After one week at 40°C, a ~7% decrease in the main species and an ~8% increase in the acidic species were observed compared to baseline (T0), indicating that the charge profile is highly susceptible to thermal stress.

 

 

Discuss Your Early-Stage Developability Assessment Projects with Our Experts

Contact Us

Watch Expert-Led Webinars

Early-Stage Developability Assessment for Lead Optimization

 

 

In this webinar, you will gain valuable insight into:

 

  • High-throughput assays with robust performance and high sensitivity for biophysical and PK profiling, including AC-SINS, BVP/DNA/insulin ELISA, FcRn affinity and serum stability.
  • Integrated developability assessments combining in silico modeling and in vitro assays to identify potential risks in early stage.
  • Micro-developability strategy for new modalities.

 

 

Watch the Webinar On-Demand Now

 

Mass Spec Enables More Definitive Biologics Drug Discovery and Development

 

 

In this webinar, you will learn:

 

  • Comprehensive approaches to Mass Spec-based protein characterization, tailored for biologics.
  • Advanced Mass Spec techniques, including cIEF-MS for charge variants, HTP Intact Mass, glycan analysis, de novo sequencing, and more.
  • How customized Mass Spec methods identify and resolve anomalies detected in routine testing like CE-SDS and icIEF.

 

 

Watch the Webinar On-Demand Now

 

Download Our Posters

Micro Developability for Early-Stage Lead Optimization

 

 

Download Now 

 

In-Depth SPR Binding Assays Supporting Drug Discovery

 

 

Download Now 

 

Micro Developability: Customized Developability Package for Lead Optimization

 

Micro Developability provides a suite of HTP, low-sample-consumption assays that can evaluate biophysical properties, pharmacokinetics (PK), and manufacturability in early stages. Complemented by powerful in silico screening, this platform integrates wet-lab in vitro assays into predictive models, providing actionable insights for lead optimization in early-stage drug discovery.

 

Ready to kick off your early-stage developability assessment projects? Micro Developability delivers exactly what you need: high throughput, minimal sample use, and customized package tailored to your molecules.

Request a Quote for Early-Stage Developability Assessment Services

 

 

 

 

Stay On The Forefront Of Biologics
Discovery & Development

Follow us on LinkedIn